Nov 14, 2024 8:30 am EST Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
Nov 7, 2024 4:05 pm EST Achieve Life Sciences Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
Oct 24, 2024 8:00 am EDT Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 7, 2024
Oct 23, 2024 8:00 am EDT Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public Meeting
Oct 16, 2024 8:00 am EDT Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline
Oct 10, 2024 8:00 am EDT Achieve Life Sciences Announces Completion of Enrollment in ORCA-OL Clinical Trial & Successful Outcome of the First Data Safety Monitoring Committee Meeting
Oct 1, 2024 8:45 am EDT Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs
Aug 26, 2024 4:30 pm EDT Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors
Aug 13, 2024 4:01 pm EDT Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
Jul 31, 2024 8:00 am EDT Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence